123 related articles for article (PubMed ID: 15912853)
1. [Optimal osteoporosis strategy?].
Scharla S; Reichenhall B
Krankenpfl J; 2005; 43(1-3):65. PubMed ID: 15912853
[No Abstract] [Full Text] [Related]
2. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
3. Drugs for prevention and treatment of postmenopausal osteoporosis.
Med Lett Drugs Ther; 2000 Oct; 42(1090):97-100. PubMed ID: 11035622
[No Abstract] [Full Text] [Related]
4. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
5. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
6. New osteoporosis strategy: boosting bone growth.
Johns Hopkins Med Lett Health After 50; 2004 Apr; 16(2):4--5. PubMed ID: 15088565
[No Abstract] [Full Text] [Related]
7. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year.
Musialik J; Petelenz M; Gonciarz Z
Scand J Gastroenterol; 2005 Jul; 40(7):873-4. PubMed ID: 16109666
[No Abstract] [Full Text] [Related]
8. Teriparatide for postmenopausal osteoporosis.
Drug Ther Bull; 2004 Dec; 42(12):93-5. PubMed ID: 15587764
[TBL] [Abstract][Full Text] [Related]
9. Bone anabolic agents: the unanswered queries.
Adami S; Viapiana O; Gatti D
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):257-9. PubMed ID: 15228496
[No Abstract] [Full Text] [Related]
10. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis.
Dempster DW
J Bone Miner Res; 1997 Aug; 12(8):1152-4. PubMed ID: 9258744
[No Abstract] [Full Text] [Related]
11. [Reduction of the Nordin index after therapy with oral alendronate in patients with postmenopausal osteoporosis].
Busi S; Catalano A
Clin Ter; 1995 Dec; 146(12):857-9. PubMed ID: 8681505
[TBL] [Abstract][Full Text] [Related]
12. Treating osteoporosis with teriparatide: many unknowns?
Shukla VK
Issues Emerg Health Technol; 2003 Nov; (51):1-4. PubMed ID: 14610756
[TBL] [Abstract][Full Text] [Related]
13. New drug builds bone.
Harv Womens Health Watch; 2001 Jul; 8(11):2. PubMed ID: 11511464
[No Abstract] [Full Text] [Related]
14. Teriparatide (forteo) for osteoporsis.
Med Lett Drugs Ther; 2003 Feb; 45(1149):9-10. PubMed ID: 12571538
[No Abstract] [Full Text] [Related]
15. Results of special studies with alendronate.
McClung M
Int J Clin Pract Suppl; 1999 Apr; 101():67-72. PubMed ID: 12669743
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
17. Sequential parathyroid hormone/alendronate therapy for osteoporosis--robbing Peter to pay Paul?
Horwitz M; Stewart A; Greenspan SL
J Clin Endocrinol Metab; 2000 Jun; 85(6):2127-8. PubMed ID: 10852439
[No Abstract] [Full Text] [Related]
18. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
19. [Teriparatide--new value in osteoporosis treatment: treatment guidelines].
Korsić M; Kastelan D
Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560
[TBL] [Abstract][Full Text] [Related]
20. Anabolic therapy for osteoporosis.
Bilezikian JP
Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
